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This paper examines how the oncomouse became a patentable invention. The 
oncomouse began life in the laboratory, where it was genetically modified for use as a 
research tool to assist with the study of human cancer. Its design, a product of genetic 
modification, made the oncomouse potentially patentable subject matter. The United 
States was the first jurisdiction to award the patent and several others followed. 
However, the question of animal patenting was most contentious in Europe and 
Canada. In this paper I examine debates about animal patenting within the legal and 
moral spaces created by United States, European and Canadian patent law, focusing 
on differences that emerged in each case. I argue that oncomouse as a patentable 
invention was made possible and acceptable as different ways of being mouse as 
natural animal, research tool and invention were made to cohere: that is as they were 
made to overlap and depend upon one another. In the paper I use the term “cohere” to 
describe the logic of animal patenting that emerged with, and was essential to, the 
outcome in each jurisdiction. I describe an ontological politics of connecting and 
separating different ways of being mouse, as the oncomouse’s genetic modification, 
risks, benefits, and suffering were juxtaposed with patent law, precedent, laboratory 
protocols, and understandings of human agency and control. As connections and 
separations were made, a relation, “natural animal-research tool-invention”, was 




Now the opportunity to patent an object, and in this case animals, 
then creates an environment in which someone can hope to obtain a 
financial return if they choose to invest in that process…. That’s our 
system. You may like it – you may not like it. (Philip Leder)2 
 
The patenting of animals is out of step with both religious and 
modern secular beliefs. From a religious viewpoint it is offensive, 
even blasphemous, for humanity to claim to have “invented” an 
animal; it is God, not humanity, who creates life. From a secular 
viewpoint an increasing number of people view animals not as 
existing simply for our use and profit, but as our fellow creatures – 
capable like us of feeling pain and suffering. (British Union for the 
Abolition of Vivisection)3 
 
These statements are responses to the patenting of the Oncomouse, a genetically 
modified mouse that was the first animal to be patented. The Oncomouse began its 
life in a laboratory where it was set to work as a research tool to assist with the study 
of cancer. What made this mouse different from its laboratory rodent brothers and 
sisters before it was its design, or more specifically the means by which it was 
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designed, that enabled it to become patent-eligible subject matter. As the quotes 
above suggest, the patentability of this animal generated a debate about the 
relationship between human and non-human animals: what is appropriate, moral, right 
and good. 
 
The first jurisdiction to allow the patent was the United States, and several others 
followed. However, the matter was most contentious in Europe and Canada, where 
various groups, committees and courts of law debated the acceptability of patenting 
the oncomouse over a twenty-year period. In each case, there was opposition to 
animal patenting based on moral concerns, but the extent to which such concerns 
were able to influence the outcome differed and was contingent upon interpretations 
of patent legislation in each jurisdiction. The United States awarded the patent in full; 
in Europe it was awarded in a modified form; and Canada remains the only 
jurisdiction in the world to have rejected animal patenting. It is these differences that 
make a comparative analysis of the United States, European and Canadian debates so 
compelling. 
 
In my analysis I focus on the connections and separations made between mouse as 
natural animal, research tool and invention, as interpretations of patent legislation 
were made by patent officers and courts of law within the legal and moral spaces 
created by the United States Patent and Trademarks Office, the European Patent 
Office and the Canadian Patent Office. I argue that oncomouse as a patentable 
invention is achieved and acceptable when mouse as natural animal, research tool and 
invention overlap and depend upon one another: that is when they cohere.4 I am using 
John Law’s conceptualisation of “coherence”5 to describe the logic of animal 
patenting that emerges with, and is essential to, the outcome in each case. Law uses 
the concept of “coherence” to describe an understanding of how objects can be 
simultaneously singular and multiple. The singularity of an object, in this case the 
oncomouse as patentable invention, is contingent upon multiple enactments of that 
object, in this case as natural animal, research tool and invention, that intersect, 
overlap and depend upon one another – that cohere. Law describes this way of writing 
about objects as a “fractional knowing” that does not efface the object’s multiplicity.6 
Law’s work extends that of scholars in Science and Technology Studies (STS) who, 
using actor-network theory as the starting point, have explored the explanatory 
potential of an empirical metaphysics7, multiplicity8, ontological politics9, and 
ontics10. These scholars hold that people and things, humans and non-humans, are 
contingently made to belong to the real within networks of relations that are fluid and 
emergent. These networks are formed as the practices and negotiations of science, 
law, policy, and public debate link certain things together and keep other things apart. 
This approach is an empirical undertaking that addresses how things, such as an 
animal as an invention, come to occupy the attention of scientists, patent officers, 
courts of law, and citizens, and how they either persist or pass away as objects of 
enquiry and interest. This approach emphasises the material and intellectual culture 
and work that is needed to bring objects of science, and in this case objects of patent 
protection, into being as entities that belong to the real.11 
 
The contingency of being oncomouse has been beautifully espoused in Haraway’s 
analysis of OncoMouse™12, the commercial entity sold under licence by Du Pont. 
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For Haraway, OncoMouse™ is kin, a mouse that suffers so that we may live, and is 
born into the “matrices” of “The New World Order”.13 This New World Order 
announces itself with the products of corporate biology, among which OncoMou
is an example par excellence, by being the first patented animal in the world. In 
Haraway’s account, the oncomouse is a material and semiotic entity, a hybrid






Like Haraway, I am interested in the contingency of being oncomouse but I focus 
specifically on negotiations about the patentability of this mouse, and on the links and 
separations that are made between mouse as natural animal, research tool and 
invention. I examine how the oncomouse’s genetic modification, risks, benefits, and 
suffering are juxtaposed with patent law, precedent, laboratory protocols, and 
understandings of human agency and control to produce the relation “natural animal-
research tool-invention” upon which the patenting of the oncomouse depends. In the 
discussion that follows, I draw upon two interviews with the one of the mouse’s 
inventors, scientific papers, patent applications, and transcripts of patent disputes. I 
begin with mouse as research tool and examine the connections and separations made 
that enabled mouse as natural animal and mouse as research tool to cohere. I then 
examine the patenting of the oncomouse in the United States, Europe and Canada, 
paying particular attention to the connections and separations made between 
suffering, risks, benefits, patent law, and moral concerns. I conclude by considering 
what is gained by examining the patenting of the oncomouse in this way. I suggest 
that the analysis I develop in this paper enables a form of transparency not otherwise 
possible because it reminds us that our reality - our way of moving forward - is not 
given in the order of things but made (chosen), and that it could have been otherwise. 
 
Oncomouse as research tool 
 
The Oncomouse began its life at Harvard Medical School in the laboratory of Philip 
Leder and his colleagues who were interested in the role and function of oncogenes15 
in the formation of cancer. This research evolved from Leder’s earlier work into the 
cause of a particular cancer called Burkitt lymphoma. Leder found in this case that 
one of the genes that controlled growth in malignant cells, a c-myc gene, had been 
moved from its normal chromosomal location, and in the process had become 
activated as an oncogene. Leder and his colleagues hypothesised that the activation of 
this oncogene had something to do with its translocation and was activated through a 
regulatory rather than coding disturbance. They set out to test this hypothesis using 
transgenic mice.16 
 
We wanted to take the same genes, more-or-less, the myc gene which 
was involved in Birkitt lymphoma, and we wanted to introduce it into 
a mouse to ask if it could be responsible for the formation of 
additional malignancies. So really the precise purpose of that work 
was to demonstrate that c-myc was able to act as an oncogene 
within the context of an animal.17 
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Making transgenic animals requires skill, and Leder had tried and failed to do this in 
the past.18 However, at Harvard Medical School Leder was fortunate to have a post-
doctoral fellow, Tim Stewart, who “in addition to having a wonderful brain had good 
hands as well” and was able to micro-manipulate mouse oocytes and introduce DNA 
into them under conditions that were “exacting and demanding”.19 The mouse was 
modified using recombinant DNA techniques20 to become a model for human disease 
that allowed Leder and his colleagues to study cancer causing oncogenes by 
extrapolating from the mouse to the human. “So we just sort of used them 
interchangeably”.21 
 
It was tough going, and in my interview with him, Leder described the mixture of 
excitement and fear with which they greeted the first of their transgenic mice to 
develop a tumor. 
 
So when Tim brought up the first mouse and showed it to us it was 
an incredibly exciting thing. Whenever we get a result of that 
importance, many scientists, myself included, get frightened. What if 
this is not right? What if this is wrong? We’ve got to go back and 
repeat it or somebody else can repeat it for us. But there was an 
awful lot of excitement surrounding that because it opened doors to 
experiments that you could really now – important hypotheses such 
as the Birkitt lymphoma one – answer using a mammalian system.22 
 
The paper announcing the mouse model describes the modification of 13 strains of 
mice using four different artificial constructions in which a mouse mammary tumor 
virus promoter (MMTV) had been fused to various segments of a normal mouse c-
myc gene. The insertion of these fusion genes into mice was an attempt to simulate 
the translocation of the oncogene observed in cases of Burkitt lymphoma. Two of the 
13 mice developed mammary adenocarcinomas in early pregnancy. In one of these, 
the progeny that inherited the fusion gene also developed mammary adenocarcinomas 
during their second and third pregnancies. As a research tool these mice could be used 
to investigate levels of oncogene expression in tumour formation and how this might 
be influenced by the chromosomal location of the gene. The mice could also be used 
to test tumour-inducing and tumour-preventing agents and to provide a source of 
cancer cells for research.23 
 
Oncomouse was purposefully designed using genetic manipulation techniques to 
develop cancer and to be a research tool for use in a laboratory setting. At the same 
time, oncomouse was a natural animal: a mouse that needed to be housed, fed, and 
cared for, and which had the capacity to suffer, to feel pain and when threatened to 
react as an animal interested in its own survival.24 However as a research tool, it is 
the laboratory life of the mouse that takes precedence, and practices of care becom
adjunct to and supportive of this way of being mouse.  
e 
 
Lynch has described what he regards as a transformation from naturalistic animal to 
analytic animal in his observations of researchers experimenting with rats in a 
neuroscience laboratory. In Lynch’s case, researchers engaged in rituals of killing that 
they referred to as “sacrifice” that enabled them to reduce the holistic animal to its 
component parts: to cells, brain, and neurons. He argues that the “naturalistic animal” 
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is an entity of the “commonsense life world”, that of our ordinary perception within 
everyday life: “a living being, a subject for-itself as well as in-itself”25 in a relation 
with humans such as that between pet and owner and the reciprocity this entails of 
understanding and emotional attachment.26 Laboratory practices transform rats from 
“holistic” and “naturalistic” creatures into “analytic objects of technical 
investigation”.27 Lynch’s argument posits different points of view of the animal that 
are contradictory, and the process by which one view becomes dominant. However, 
when he talks about the rat as an analytic animal he describes a “product of work”, 
“ostensibly and artifact”, “shaped by human agency” and “a product of human 
intervention”.28 It is this work that I want to draw attention to, because in the case of 
the oncomouse it brings mouse as research tool into being, not I would argue, as 
Lynch suggests, through the transformation of the naturalistic animal, but through 
juxtaposing natural animal and research tool in ways that overlap and depend upon 
one another. 
 
The laboratory practices undertaken by Leder and his colleagues result in a series of 
contingent separations and connections that perform mouse as research tool. The 
oncomouse is an animal that suffers, it feels pain, and reacts in ways that show it is 
interested in its own survival. At the same time it is connected to humans as its animal 
body is modified to develop cancer and produce tumor cells analogous to those 
produced in the human body. Its mice offspring help to construct lines of inheritance 
along which cancer-causing genes travel. In the course of scientific problem-solving 
and ethical oversight, the mouse becomes both a natural animal that is analogous to a 
human animal and a research tool for scientific problem-solving. The mouse’s 
suffering is set in relation to the suffering of humans with cancer and justified by the 
magnitude of the problem it is designed to solve and the potential alleviation of 
human suffering this could achieve. Leder said it came as a shock to him that people 
would not immediately see the advantage in using mice in this way: 
 
It never really occurred to me that if what you want to do is alleviate 
human suffering, particularly a disease like cancer for which there 
is so much pain involved, that anybody could possibly see this as a 
wrong.29 
 
This relation between human and animal suffering is a risk/benefit calculation that 
makes tolerable the mouse that suffers by connecting it to human suffering and the 
value of oncomouse as research tool in the alleviation of that suffering. The mouse is 
made to function seamlessly as both natural animal and research tool: it is made to 
cohere. 
 
Oncomouse as invention 
 
United States 
Leder’s research was funded by the pharmaceutical company Du Pont, and as such 
was part of an emerging trend at the time in industry-funded research.30 Leder’s 
contract with Du Pont obliged him to report commercially promising outcomes to the 
Harvard Office of Technology Licensing and Industry, and Du Pont had priority over 
the marketing of such products. These university-industry partnerships transformed 
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the traditions of gentlemanly science, with its sharing of resources and peer review, 
into a more competitive and contractual relationship31 that in this case propelled the 
mouse out of the laboratory and into the patent office. As Leder explains: 
 
One of the elements of the creation of these mice - these animal 
models of human disease – was that it coincided with a time that the 
Supreme Court had just decided that all life forms could be patented. 
And as an obedient employee of Harvard Medical School, Tim and I 
reported this invention to our Office of Technology Licensing as an 
invention and a discovery, which we disclosed to them and which 
potentially would be patentable.32 
 
The decision to which Leder refers is that by the Supreme Court to patent a 
bacterium. In 1972, the United States Patent and Trademarks Office (USTPO) was 
asked to determine whether an oil eating bacterium created by Ananda Chakrabarty 
was an invention. This was the first time the patent office had been asked to consider 
a living entity as potentially patentable. Its initial rejection of the patent and 
subsequent appeal by Harvard brought it in June 1980 to the Supreme Court, which 
held by a very slim margin of 5 to 4, that the bacterium was not a product of nature 
but a product of manufacture and therefore deserved a patent. One of the judgements 
stated that: 
 
Here, by contrast, the patentee has produced a new bacterium with 
markedly different characteristics from any found in nature, and one 
having the potential for significant utility. His discovery is not 
nature's handiwork, but his own; accordingly it is patentable subject 
matter under § 101.33 
 
Harvard filed a patent application on the oncomouse with the USPTO in June 1984, 
naming as inventors Philip Leder and Timothy Stewart. The abstract describing the 
invention read as follows: 
 
A transgenic non-human eukaryotic animal whose germ cells and 
somatic cells contain an activated oncogene sequence introduced 
into the animal, or an ancestor of the animal, at an embryonic 
stage.34 
 
The application was broad and covered all non-human animals modified in this way. 
 
The very same question that had occupied the attention of the USPTO in 1972 now 
compelled its attention again. Was the oncomouse nature’s handiwork or Leder’s? 
The answer was in part determined by the outcome of another patent application, 
announced on 7 April 1987, the subject of which was a multicellular polyploidy 
oyster. The USPTO rejected this application because it lacked a novel step but the 
oyster was determined to be “patent-eligible subject matter” in keeping with the 
USPTO’s declaration at this time that it considered all “non-naturally occurring, non-
human multicellular living organisms, including animals, to be patentable subject 
matter”.35 This determination had direct implications for Harvard’s application and 
on 12 April 1988, the oncomouse made history as the first animal to be awarded a 
patent. In what way is a living creature enacted as a product of manufacture and as a 
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patentable invention? And how does this enactment of oncomouse sit in relation to 
other ways of being mouse? 
 
The USPTO defines patentable subject matter as any new and useful process, 
machine, article of manufacture or composition of matter. 36 Natural phenomena are 
not patentable subject matter but inventions can comprise, use, or modify nature, as 
was the case with Chakrabarty’s oil-eating bacterium. With the decision of the 
USPTO to patent the oncomouse, animals became patent eligible subject matter in the 
United States. The oncomouse was genetically modified and according to the USPTO 
was not nature’s handiwork but that of Leder and Stewart. Patents give the owner the 
right to exclude others from using, manufacturing, selling, offering to sell or 
importing the patented invention for a period of about twenty years. They comprise a 
mechanism that enables the owner a return on his/her investment and acts as an 
incentive for further investment. As a patented invention, the oncomouse is performed 
as a tool that can be sold under licence to scientists interested in understanding, 
treating and possibly curing cancer and it becomes a source of revenue for its 
inventors and the patent owner. 
 
With the USPTO’s decision, the human made qualities of the oncomouse were given 
priority. This set the oncomouse apart from its naturally-bred brothers and sisters and 
opened the way for other animals to be inventions. In the United States, humans are 
now able to invent animals and thus avail themselves of another avenue through 
which payment for animal labour and animal products can be transacted. However, 
there was opposition to this new state of affairs. At hearings in 1987 and 1989, animal 
rights activists argued that animal patents would degrade animals, environmentalists 
argued that genetically modified animals might escape and contaminate the 
environment, clerics argued that patenting reduced God’s creatures to material 
objects, and farmers worried about the economic consequences for small farms.37 
Opponents attempted to separate out the natural animal as an autonomous moral 
entity that would be harmed by allowing animals to be patented and thereby disrupt 
the relation “natural animal-research tool-invention” that the patenting of animals 
established. However, U.S. patent law contains no basis for the USPTO or courts of 
law to deny a patent on the basis of morality and the opponents were unsuccessful. As 
Bagley notes, it is a “de facto system of patenting first, and asking questions later with 
regard to morally controversial biotech subject matter”.38 Oncomouse as a moral 
entity was not the business of the USPTO, and space for it was not opened up 
elsewhere, as for instance by congress. In the United States it was the connections 
between the oncomouse’s novel physical attributes, its human design and ability to 
assist with the study and treatment of cancer – all features that made it a new and 
useful composition of matter – that prevailed. It was with these connections, and their 
separation from moral concerns, that the decision to award the patent was made. 
Mouse as “natural animal-research tool-invention” was made to cohere, and a logic of 
animal patenting was established. 
 
Europe 
In Europe however, two clauses in the patent legislation created a legal and moral 
space in which natural animal as an autonomous moral entity could be made present: 
Article 53(b) prohibited the patenting of plant and animal varieties, and Article 53(a) 
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prohibited patents on inventions that were contrary to public morality (an ordre 
public).39 Harvard’s patent application was initially rejected by the European Patent 
Office (EPO) on grounds that the oncomouse was an animal variety and therefore the 
patent was prohibited under Article 53(b). Additionally, the patent office ruled that it 
could not be assumed that the modification in mice could be extended to all other 
animals (Article 83 EPC). Harvard appealed this decision and the Board of Appeal 
ruled in Harvard’s favour, stating that Article 53(b) applies to some but not all 
animals and that “in the absence of serious doubts substantiated by verifiable facts” 
there was no reason to refuse the patent under Article 83.40 However, the board 
expressed the view that in the case of a genetically manipulated animal there could be 
compelling reasons to consider article 53(a), and they remitted the case to the 
Examining Division of the EPO for further consideration.41 
 
Article 53(a) sets the requirements of a patent in relation to questions of morality but 
leaves open to interpretation the criteria and method of determining whether or not 
morality is a bar to patenting. The Examining Division chose to employ a “balancing” 
test: 
 
[T]he question of morality has to be examined and possible 
detrimental effects and risks have to be weighed and balanced 
against the merits and advantages aimed at.42 
 
It weighed and balanced claimed benefits, such as remedying human disease, against 
the risk that oncomice might escape into the environment where their genetic 
modification might be transferred to wild mice, and against the risk of cruelty to 
animals. The Examining Division determined that the invention would be of benefit in 
remedying human cancer because genetically modified mice of this sort were unique 
and there were few suitable alternative models. They conceded that the potential 
introduction and spread of genetically modified animals into the environment might 
cause harm, but argued that this risk, and that of animal cruelty, did not present a 
significant bar to patenting because such matters were best dealt with by laboratory 
protocols: this shifted questions of morality onto national laws and guidelines that 
govern the use of animals in scientific research.43 With these connections and 
separations, oncomouse as research tool was deemed useful and of benefit, and any 
risks of environmental harm and animal suffering were relegated to the laboratory for 
management: a separate moral space to that of patents. With the apportioning of harm 
and suffering as matters for laboratory protocols, the utility of the invention alone 
became a matter for the patent office. The Examining Division concluded that the 
invention could not be considered “immoral or contrary to public order” and the 
patent should not be denied.44 
 
The patent was granted by the EPO on 13 May 1992. However, between 18 
December 1992 and 13 February 1993, seventeen oppositions were filed against this 
decision. The Opposition Division of the EPO commenced opposition proceedings 
that continued until 16 January 2003. At the outset of these proceedings, the 
Opposition Division rejected as inadmissible all opponents’ objections except those 
put forward under Article 53 (a), those being objections of direct relevance to the 
decision of the Examining Division. 
 
© ESRC Genomics Network.
            Genomics, Society and Policy 
            2008, Vol.4, No.2, pp.21-35 
 
_____________  29 
 
Genomics, Society and Policy, Vol.4, No.2 (2008) ISSN: 1746-5354 
 
Opposition came primarily from animal rights groups across several European 
countries: from Britain, the British Union for the Abolition of Vivisection (BUAV), 
and Compassion in World Farming (CWF); from Germany, Bundesverband der 
Tierversuchsgegner, Evangelischer Stadtkirchenverband Köln, and Deutsches 
Tierhilfswerk; from Switzerland, Keine Patent auf Leben; and from Austria, Wiener 
Tierschutsverein. In addition, several German political groups, such as the Ökologisch 
– Demokratische Partei, Fraktion Bundnis 90/ Die Brunen im Bayer, Bundesland 
Hessen, submitted appeals, as did a small number of German citizens.45 The joint 
submission from BUAV and CWF, for instance, argued that, if the Examining 
Division had carefully weighed usefulness and suffering, animal suffering would 
exceed any benefit. The oncomouse was of limited usefulness when it came to testing 
such things as anti-cancer drugs, and non-animal alternatives were available. They 
challenged the breadth of the patent, arguing that it potentially extended animal 
suffering to all mice and other research animals: 
 
The Opponents believe that most members of the public would reject 
as immoral the production of a dog or monkey designed to develop 
cancer. Even if an oncomouse was acceptable to some people, the 
Opponents have no doubt that most would view an ono-dog or onco-
chimpanzee as morally unacceptable.46 
 
They regarded the alteration of the natural animal’s genetic structure as an act that 
was in itself immoral, and as an offence compounded by the fact that it resulted in 
suffering. Opponents argued that animal suffering cannot be weighed against human 
suffering because it is morally repugnant for humans to deliberately cause harm to 
animals and the ends do not justify the means: 
 
The Opponents believe that it is contrary to morality for humanity to 
change an animal’s genetic structure with the clear purpose of 
predisposing that animal to suffering. 
 
And as the opening quote showed, they argued it is blasphemous to claim that humans 
have invented an animal because only God creates life and, even from a secular 
standpoint, claiming an animal as an invention is at odds with the “modern approach 
to animals” that regards them “not as existing simply for our use and profit, but as our 
fellow creatures - capable like us, of feeling pain and suffering”.47 For the BUAV and 
CWF the oncomouse was “designed to suffer and die” and no human should condone 
such deliberate harm. These opponents used 53(a) to argue for an autonomous moral 
entity: an animal that has rights and needs of its own that would be denied if an 
animal were to be genetically modified and become an invention. Patents, they 
contended, were “the very antithesis of a caring relationship” because they allowed 
“the patent holder to exploit the patented animal”.48 The offence is the disruption of 
the natural animal as a consequence of its deliberate genetic modification: an offence 
exacerbated by allowing the patent. Opponents did not accept the connections and 
separations between mouse as natural animal, research tool and invention that made 
mouse as patentable entity acceptable. Nor did they accept that matters of morality 
would be adequately managed within the laboratory. They viewed the very act of 
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genetic modification as violating the mouse’s moral autonomy and integrity and 
laboratory protocols that permitted such modification as morally unacceptable. 
 
The Opposition Division ruled against the opponents and upheld the separation of 
moral concerns and utility established by the Examining Division. Accordingly the 
patent was maintained, but in an amended form that applied to rodents only. This 
restriction was a concession by Harvard made on 24 April 1997 to narrow the scope 
of their claim to rodents.49 Opposition continued however and caused further delays 
as the patent office duly conducted public hearings. The final settlement was 
announced on 6 July 2004 and it was to uphold the patent as granted, being applicable 
to rodents only.50 In Europe the oncomouse and its onco-rodent brothers and sisters 
became inventions more than twenty years after the priority date of the patent, which 
was 22 June 198451: a symbolic victory perhaps but nevertheless one that established 
the relation “natural animal-research tool-invention” and the logic of animal patenting 




In 1985, Harvard University applied for a Canadian Patent on the oncomouse and 
other transgenic non-human eukaryotic animals whose germ cells and somatic cells 
contain an activated oncogene sequence introduced into the animal, or an ancestor of 
the animal, at an embryonic stage. In Canada, as in the United States and Europe, 
there was opposition to animal patenting from religious, environmental and animal 
rights groups such as: The Canadian Council of Churches and Evangelical Fellowship 
of Canada; the Canadian Environmental Law Association; Greenpeace Canada; the 
Canadian Association of Physicians for the Environment; Sierra Club; International 
Fund for Animal Welfare; and Animal Alliance of Canada.52 However, as in the 
United States, the Canadian Patent Act does not include an ‘ordre public’ limitation53 
that would allow moral concerns to be considered as possible grounds for the denial 
of a patent. Instead, the deliberations of the Canadian Patent Office on Harvard’s 
application focused on the extent to which the oncomouse satisfied the definition of 
invention in the Canadian Patent Act. The Canadian definition of “invention” is very 
similar to that in the United States Act. It is: 
 
Any new and useful art, process, machine, manufacture or 
composition of matter, or any new and useful improvement in any 
art, process, machine, manufacture or composition of matter.54 
 
And in Canada, as in the United States, bacteria have been patentable since 1982.55 
However, the question as to whether higher life forms should be patentable was 
considered by the Canadian Patent Commissioner to be “more debatable” and a 
distinction was thus made between the patentability of lower and higher life forms. 
 
The initial ruling by the Patent Examiner, in June 1993, denied the patent on the 
oncomouse as being outside the definition of invention. A further decision, in 1995, 
allowed claims to the process, the cells and plasma containing the oncogene and 
method for making the mouse, but not the mouse itself. The Commissioner held that 
an invention being a ‘manufacture or composition of matter’ was something the 
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inventor could control, and on this point he separated the gene construct from its 
animal host. The gene construct, the MMTV/myc fusion gene, was made externally to 
the body of the mouse and was therefore a composition of matter made by human 
hands. The mouse, by comparison, had been gestated in utero and was the work of 
nature: it was therefore nature and not man that made the final product. Harvard 
challenged this separation of the work of humans and nature in an appeal to the trial 
division of the Federal Court. The appeal was dismissed. The trial judge’s decision 
hinged on two points: reproducibility, and the distinction between human control and 
the work of nature: 
 
The mouse is a complex life form and many of its features are not 
under the control of the inventors…. A mouse is not “raw material’ 
which was given new qualities by the inventor…. The creation of the 
oncomouse is a marriage between nature and human intervention. 
What is involved here is the insertion of the myc gene and 
subsequent breeding… the result of the gestation process is infinitely 
variable and, in its detail, unknown.56 
 
This lack of control meant that the claimed invention was not reproducible and 
therefore not patentable subject matter. However, the outcome of a subsequent appeal 
reversed this decision and awarded the patent. The appeal court ruled that “The 
oncomouse is both unobvious and a new and useful ‘composition of matter’; therefore 
it is an ‘invention’ within the meaning of section 2 of the Act”. 57 The ruling was that 
the patent Act was silent on the patentability of non-human animals and therefore did 
not exclude such organisms. The oncomouse was a combination of human ingenuity 
and laws of nature but would not exist in nature. It required human ingenuity to bring 
it into being and was therefore appropriately a composition of matter. 
 
However, the opponents, mentioned earlier, sought to intervene and the Supreme 
Court granted them appeal standing so that they could challenge the patent.58 In the 
Supreme Court, judges were asked to rule on a single question: was the oncomouse a 
“manufacture” or “composition of matter” and therefore an invention? The Court, 
with a 5 to 4 majority, upheld the view of the Patent Commissioner that an invention, 
being a “manufacture” or “composition of matter”, was something the inventor could 
control and that the gene construct fell into this category, being made externally to the 
body of the mouse, but that the mouse had been gestated in utero and was therefore a 
product of nature. As Justice Bastarache, writing for the majority concluded: 
 
The body of a mouse is composed of various ingredients or 
substances but it does not consist of ingredients or substances that 
have been combined or mixed together by a person. Thus I am not 
satisfied that the phrase “composition of matter” includes a higher 
life form whose genetic code has been altered in this manner.59 
 
Bastarache and his colleagues were of the view that only Parliament was in a position 
to respond to concerns associated with patenting higher life forms and to amend the 
Patent Act.60 Whereas the dissenting minority argued that even though inventions 
such as genetically modified animals had not been anticipated at the time that the 
Patent Act was drafted, they should be considered inventions in the same way other 
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unanticipated inventions have been: such things as moon rockets, antibiotics, 
telephones and email. They proposed that Canada, with intellectual property 
legislation similar to that of the United States and other countries that have granted 
the patent, should arrive at a similar outcome.61 
 
The majority decision of the Canadian Supreme Court upheld certain connections and 
separations made by previous rulings in the case. For instance, single-cell organisms 
were separated from multicellular ones, and only the former could be inventions. 
Human handiwork was connected to the gene construct but separated from the 
gestation of the mouse in utero and its birth. Human control and reproducibility were 
connected to the gene construct but not to the mouse. These connections and 
separations did not establish a relation “natural animal-research tool-invention” and 
there was no accompanying logic of animal patenting to set the precedent for other 
animals to be patented in Canada. The matter of animal patenting was deferred to the 
parliament.62 In 2002, the Parliament’s Canadian Biotechnology Advisory Committee 
recommended that the Canadian Patent Act be amended to allow the patenting of 
higher life forms. However, the Parliament has been slow to act and, at the time of 




In Canada, Europe and the United States, separations and connections were made 
between enactments of mouse as natural animal, research tool and invention that 
resulted in a different outcome in each jurisdiction. In the United States, technical 
questions were separated from moral ones and connections were made between the 
oncomouse and other patent-eligible subject matter. The oncomouse was a product of 
human ingenuity that was new and useful, and questions of morality were not the 
business of the patent office. In Europe, concerns about animal welfare and risks to 
the environment were separated from judgements about the invention’s utility. 
Welfare concerns, such as animal cruelty and the risk of gene flow to wild mice, were 
matters to be dealt with by laboratory protocols. Questions of benefit and the utility of 
the invention were matters for the patent office. In Canada, the oncomouse’s gestation 
in utero was connected to nature and not to human control. Oncomouse could be 
natural animal and research tool but not a new and useful art, process, machine, 
manufacture or composition of matter. Only the gene construct was connected to 
bacteria and other patentable entities. 
 
For the oncomouse to become an invention it needed to be enacted as natural animal, 
research tool and invention in ways that overlapped and depended on one another: in 
ways that cohered. In other words, it needed to be integrated into a seamless and 
coherent logic of utility and human control. In each jurisdiction, opponents attempted 
to disrupt this logic by focusing on moral concerns. Opponents positioned themselves 
as guardians of an autonomous moral subject - the natural animal. However, decisions 
made by divisions within patent offices and courts of law separated out moral 
concerns as not relevant to the question of animal patenting in each case. If there was 
a battle to be fought on moral grounds, it was to be fought elsewhere, in the 
laboratory or in the parliament, but not in the patent office. This separation enabled 
utility to prevail as the defining enactment of oncomouse as invention, and that 
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determined whether or not the relation mouse as natural animal-research tool-
invention would cohere enough to award the patent. In the United States and Europe 
this relation prevailed; in Canada it did not. In Canada, the connections and 
separations between the oncomouse’s autonomous nature and its genetically modified 
nature, and the extent to which the latter enabled the oncomouse’s biology to be under 
human control and reproducible, became the locus of separation. 
 
To conclude, I want to emphasise that the relationship between humans and animals 
that animal patenting establishes, and the decisions made about whether animal 
patenting is right, appropriate, moral or good, are highly contingent upon what the 
animal and its component parts are set in relation to. In the United States and Europe, 
opposition to animal patenting failed because morality was separated out as not the 
business of the patent office, whereas in Canada, opposition won the day, not by 
winning the moral argument, but because it hinged on the definition of patent-eligible 
subject matter, which is core business of the patent office and of courts of law 
charged with determining such matters: it could not be separated out. The issue at 
stake in Canada was whether and to what extent the definition of patenting and the 
oncomouse could be connected. The gene construct connected the mouse did not. 
 
Therefore, the question as to whether or not animals should be patented was not a 
matter resolved with reference to some essential quality of animals or quality of the 
things patented in the past to which animals were compared. As I have shown, it was 
answered in practice by the extent to which the oncomouse was set in relation to the 
practices, processes and deliberations of laboratories, patent offices and courts of law 
in different jurisdictions. The contingency of enactments of mouse as natural animal, 
research tool and invention and of the way each enactment overlaps with and depends 
upon the others, determines the outcome and establishes the logic of patenting, that in 
the United States and in Europe made animal patenting acceptable, right and good 
(although not to the same extent), and in Canada did not. 
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